In 2017, Ricciardelli et al. found that KRT5 mRNA expression was consistently higher in chemotherapy-resistant cells compared to chemotherapy-sensitive primary serous ovarian cancer cells and that the number of serous ovarian carcinomas with high KRT5/KRT6 or high KRT5 protein expression significantly increased following carboplatin chemotherapy [45]. This evidence concerns the gene KRT5 and ovarian serous adenocarcinoma.